BioTuesdays

Category - Markets

Moleculin Logo
Markets

Roth starts Moleculin Biotech at buy; PT $8

Roth Capital Partners initiated coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $8 price target. The stock closed at $1.69 on Dec. 20. “Our Moleculin bull thesis is based solely on its liposomal...

December 21, 2017
ConforMIS
Markets

BTIG ups ConforMIS to buy; PT $4

BTIG upgraded ConforMIS (NASDAQ:CFMS) to “buy” from “neutral” with a price target of $4. The stock was quoted at $2.58, up 30 cents, in afternoon trading on Dec. 20. ConforMIS designs and manufactures customized knee...

December 20, 2017
Organigram
Markets

Mackie ups Organigram price target to $5

Mackie Research raised its price target for Organigram Holdings (TSX:OGI) to $5 from $4 after the company completed a $57.5-million offering of units at a price of $3.50 a unit. The stock closed at $3.70 on Dec. 18...

December 19, 2017
Leerink Logo
Markets

Leerink outlines 2018 outlook of healthcare shares

Leerink is recommending that healthcare investors, after a market-beating 2017, look for ways to keep up with what will likely be a strong broader stock market in 2018. “We encourage use of higher-beta healthcare and...

December 18, 2017
Catalyst
Markets

Ladenburg ups Catalyst Bioscience PT to $14.25

Ladenburg Thalmann raised its price target for Catalyst Biosciences (NASDAQ:CBIO) to $14.25 from $11 after the company modified the Phase 1/2 protocol of CB 2679d that should accelerate the timeline to initiation of a...

December 18, 2017
Restoration Robotics
Markets

Roth starts Restoration Robotics at buy

Roth Capital Partners launched coverage of Restoration Robotics (NASDAQ:HAIR) with a “buy” rating and price target of $7.50. The stock closed at $4.86 on Dec. 15. Restoration is focused on developing and commercializing...

December 18, 2017
GlycoMimetics
Markets

Stifel ups GlycoMimetics price target to $23

Stifel raised its price target for GlycoMimetics (NASDAQ:GLYC) to $23 from $17 after the company presented incremental Phase 1/2 data for GMI-1271 in both relapsed/refractory (R/R) and newly-diagnosed AML patients. The...

December 12, 2017
scPharmaceuticals
Markets

Leerink starts scPharmaceuticals at OP; PT $20

Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with an “outperform” rating and $20 price target. The stock closed at $14.92 on Dec 11. “The lead product, Furoscix (furosemide, diuresis for heart failure...

December 12, 2017
Diplomat Pharmacy
Markets

Leerink ups Diplomat Pharmacy to OP; PT to $23

Leerink upgraded Diplomat Pharmacy (NYSE:DPLO) to “outperform” and raised its price target to $23 from $20 after recent investor meetings with the company’s management and after considering several new developments. The...

December 11, 2017
Akebia Therapeutics Logo
Markets

BTIG starts Akebia Therapeutics at buy; PT $30

BTIG initiated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a “buy” rating and price target of $30. The stock closed at $15.40 on Dec. 6. Akebia is focused on the development of Vadadustat, a novel oral, once...

December 7, 2017